- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:26 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | 144 | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen | |
| Fr | CNS Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.02. | CNS Pharmaceuticals ernennt drei neue Führungskräfte im Zuge strategischer Neuausrichtung | 3 | Investing.com Deutsch | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.02. | CNS Pharmaceuticals appoints three new executives to leadership team | 2 | Investing.com | ||
| 17.02. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 17.02. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation | 368 | ACCESS Newswire | New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS... ► Artikel lesen | |
| 27.01. | CNS Pharmaceuticals' new CEO outlines strategic overhaul | 2 | Investing.com | ||
| 27.01. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Issues Letter to Shareholders | 227 | ACCESS Newswire | Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term... ► Artikel lesen | |
| 17.12.25 | CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco's departure | 2 | Seeking Alpha | ||
| 17.12.25 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.12.25 | Führungswechsel bei CNS Pharmaceuticals: Rami Levin wird neuer CEO | 9 | Investing.com Deutsch | ||
| 17.12.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces CEO Transition | 350 | ACCESS Newswire | Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company")... ► Artikel lesen | |
| 21.11.25 | CNS Pharmaceuticals: Aktionäre stimmen Kapitalerhöhung und Wahl des Verwaltungsrats zu | 2 | Investing.com Deutsch | ||
| 21.11.25 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | CNS Pharmaceuticals reports Q3 results | 2 | Seeking Alpha | ||
| 17.11.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 402 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the... ► Artikel lesen | |
| 14.11.25 | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology 30th Annual Meeting | 277 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 03.09.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference | 389 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 15.08.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 571 | ACCESS Newswire | Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| QIAGEN | 41,295 | -0,23 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,750 | +0,95 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| BIONTECH | 92,80 | -0,54 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,490 | +4,29 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 89,71 | -1,81 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| ARCELLX | 113,93 | +0,12 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| EVOTEC | 5,686 | -2,94 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,570 | +6,35 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| ERASCA | 14,260 | +4,47 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,36 | +0,46 % | Apogee Therapeutics reports FY results | ||
| AMYLYX PHARMACEUTICALS | 15,210 | +0,26 % | A Look at Amylyx Pharma's Upcoming Earnings Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,830 | -7,99 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,310 | -1,44 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| NUVALENT | 100,96 | -0,94 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,32 %) liegt der Kurs bei 3,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.